Background Deep vein thrombosis (DVT) occurs when a blood clot blocks blood flow
through a vein, which can occur after surgery, after trauma, or when a person has been …

Background In patients with noncirrhotic chronic portal vein thrombosis (PVT), the benefit of
long-term anticoagulation is unknown. We assessed the effects of rivaroxaban on the risk of …

Direct oral anticoagulants (DOACs) have proven efficacy and safety and are approved for
use in the prevention and treatment of thromboembolic events in patients with venous …

Apixaban (Apx), an oral anticoagulant drug, is a direct factor Xa inhibitor for the prophylaxis
against venous thromboembolism. Apx has limited oral bioavailability and poor water …

Introduction: The emergence of the direct oral anticoagulants (DOACs) offers patients more
convenient and accessible alternatives to warfarin or parenteral agents for the treatment of …

Apixaban (Eliquis®) is an oral, direct factor Xa inhibitor that is available for use in the
treatment and secondary prevention of venous thromboembolism (VTE). Like other direct …

Introduction To date, the available guidance on venous thromboembolism (VTE) prevention
in elective lumbar fusion surgery is largely open to surgeon interpretation and preference …

The increasing number of bariatric/metabolic operations as important alternatives for the
treatment of obesity and type 2 diabetes brought several concerns about the intensive care …

Objectives To examine the prescribing patterns and outcomes of antithrombotic regimens
after venous stent placement. Methods A total of 87 patients who received inferior vena cava …

Background To evaluate the safety and effectiveness of argatroban for the prevention of
venous thromboembolism (VTE) after posterior lumbar decompressive surgery. Methods …